23 related articles for article (PubMed ID: 1730885)
1. Hierarchal utilization of different T-cell receptor Vbeta gene segments in the CD8(+)-T-cell response to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Cerottini JC; MacDonald HR
J Virol; 1999 Nov; 73(11):9161-9. PubMed ID: 10516023
[TBL] [Abstract][Full Text] [Related]
2. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of Moloney virus-induced tumors in CBA and A mice.
Ahituv A; Naor D; Sharon R; Tarcic N; Klein BY
Cancer Immunol Immunother; 1982; 14(1):16-26. PubMed ID: 6186365
[TBL] [Abstract][Full Text] [Related]
4. The role of humoral immunity and the contribution of the F1 anti-parental effect in the rejection of a Moloney leukemia virus-induced lymphoma graft.
Asjö B; Klein E; Fenyö EM; Klein G
Cancer Immunol Immunother; 1983; 15(2):92-5. PubMed ID: 6553518
[TBL] [Abstract][Full Text] [Related]
5. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro.
Li L; Farnet CM; Anderson WF; Bushman FD
J Virol; 1998 Mar; 72(3):2125-31. PubMed ID: 9499068
[TBL] [Abstract][Full Text] [Related]
6. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.
Medema JP; de Jong J; van Hall T; Melief CJ; Offringa R
J Exp Med; 1999 Oct; 190(7):1033-8. PubMed ID: 10510093
[TBL] [Abstract][Full Text] [Related]
7. An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
White HD; Roeder DA; Green WR
J Virol; 1994 Feb; 68(2):897-904. PubMed ID: 8289392
[TBL] [Abstract][Full Text] [Related]
8. Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.
van der Hoorn FA; Lahaye T; Müller V; Ogle MA; Engers HD
J Exp Med; 1985 Jul; 162(1):128-44. PubMed ID: 3891902
[TBL] [Abstract][Full Text] [Related]
9. Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection.
Jiang D; Flyer DC
J Immunol; 1992 Feb; 148(3):974-80. PubMed ID: 1730885
[TBL] [Abstract][Full Text] [Related]
10. The immune response to Moloney murine leukemia virus-induced tumors: induction of cytolytic T lymphocytes specific for both viral and tumor-associated antigens.
Flyer DC; Burakoff SJ; Faller DV
J Immunol; 1986 Dec; 137(12):3968-72. PubMed ID: 3491152
[TBL] [Abstract][Full Text] [Related]
11. In vivo immune selection of a Moloney murine leukemia virus-induced tumor results in the loss of viral- but not tumor-associated antigens.
Jiang D; Flyer DC
J Immunol; 1990 Nov; 145(10):3502-6. PubMed ID: 1700012
[TBL] [Abstract][Full Text] [Related]
12. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
13. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
14. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
